10-20x Potential Upside: A First-in-Class Biotech Trading Below Its Own Cash
How a $83 million biotech could become the first company to drug the undruggable.
To read our full disclaimer, click here.
Note: The scenarios, probabilities, and potential return estimates discussed in this post reflect my personal assumptions and framework for thinking about risk-reward. They are not guarantees, predictions, or investment advice. Always do your own research.
For over forty years, scientists have known the single most important gene in cancer.
It’s called p53. The “guardian of the genome.” When it works, it detects DNA damage and kills defective cells before they become tumors.
When it breaks, cancer runs unchecked.
Mutations in p53 are found in more than half of all human cancers. Lung. Breast. Ovarian. Colorectal. Pancreatic. It’s the most common genetic alteration in oncology - and for decades, it’s been considered completely undruggable.
Every major pharma company has tried. Every one has failed.
Until now.
A small biotech just posted Phase 2 data showing a 34% overall response rate in heavily pretreated patients - across multiple tumor types - using a first-in-class drug that literally repairs the broken protein. In ovarian cancer, the response rate hit 46%.
The FDA granted Fast Track designation. Then Orphan Drug designation. An NDA filing is planned for Q1 2027.
The company’s market cap? Roughly $83 million.
That’s less than its own cash balance.
Let me say that differently. The market is pricing this company at a negative enterprise value - essentially valuing the drug pipeline, the patents, and the entire first-in-class platform at zero.
Here’s what makes this interesting:
Clinical data: 34% ORR across 103 patients; 46% in ovarian cancer
Regulatory momentum: Fast Track (2020) + Orphan Drug Designation (March 2026)
Cash position: $112.9 million (above the market cap)
NDA filing target: Q1 2027
Competition: Zero late-stage competitors for the same target
My rough scenario assumptions (not predictions - just how I’m framing the risk-reward):
Failure / wind-down (~60% probability): Market cap falls to ~$25-40M as cash burns down. Downside: -50 to -70%.
Ovarian cancer approval only (~25%): $1.5-2B enterprise value based on $300-400M peak sales at 4-5x. Upside: ~15-20x.
Full tumor-agnostic approval (~15%): $5-6B+ enterprise value on multi-billion peak sales. Upside: ~60-70x.
Probability-weighted expected value: ~$0.9-1.1B vs. ~$83M market cap today - roughly 10-12x risk-adjusted asymmetry.
I think the market is getting the odds wrong here.
The company is...